When the Cancer Changes: What Hormone Resistance Really Means
Your testosterone is low. Hormone therapy is working. Yet the cancer keeps growing. This is what your oncologist calls castration-resistant prostate cancer, or mCRPC.
It is a turning point, but not the end of the road. Several treatments can help at this stage. Lu-177 PSMA therapy is one of the most important advances in prostate cancer treatment in recent years.
This article explains your treatment options, how Lu-177 PSMA works, and what clinical trials say about it.
Why Prostate Cancer Becomes Hormone-Resistant
Prostate cancer cells usually need testosterone to grow. Hormone therapy blocks that growth. For many men, this works well for months or years.
Over time, cancer cells adapt. They keep growing even without testosterone. They may develop extra copies of the androgen receptor, make their own androgens inside the tumor, or use growth pathways that do not need hormones. When this happens, standard hormone therapy stops working.
The result is mCRPC — cancer that has spread beyond the prostate and no longer responds to hormone therapy. The Prostate Cancer Foundation outlines the main treatment categories used at this stage, and understanding them helps you ask better questions at your next appointment.
The Standard Treatment Options at This Stage
Several treatments are available for men with mCRPC. The right choice depends on what you have already received, your test results, and your overall health.
- Second-generation hormone therapies (ARPIs): Drugs like enzalutamide, abiraterone, darolutamide, or apalutamide target the androgen pathway more effectively than older hormone drugs. If you have not yet received one of these, your team may try it first.
- Taxane chemotherapy: Docetaxel or cabazitaxel are given by IV in cycles. They can slow cancer growth and ease symptoms. Side effects may include fatigue, hair loss, nausea, and higher risk of infection.
- PARP inhibitors: Drugs like olaparib work best in men with certain gene mutations — especially BRCA1, BRCA2, or ATM. Genetic testing shows whether these drugs may help.
- Radium-223: A radioactive drug that targets bone metastases. It may reduce bone pain and has shown a survival benefit in men with bone-dominant disease.
- Immunotherapy: Sipuleucel-T is the only FDA-approved prostate cancer immunotherapy. It is mainly used in men with mild, slow-moving disease and few symptoms.
Each of these has a role. But none uses the same method as Lu-177 PSMA therapy — and that difference matters at this stage of disease.
What Is Lu-177 PSMA Therapy
Lu-177 PSMA therapy is a type of treatment called radioligand therapy. It combines two parts: a molecule that finds prostate cancer cells, and a radioactive payload that damages those cells when it reaches them.
The targeting molecule attaches to PSMA — prostate-specific membrane antigen — a protein found in large amounts on most prostate cancer cells. When the molecule binds to a PSMA-positive cell, the radioactive lutetium-177 delivers radiation directly to that tumor cell.
This is different from external beam radiation, which targets a set area of the body. It is also different from chemotherapy, which affects all fast-dividing cells. Lu-177 PSMA is designed to find cancer cells wherever they are — bone, lymph nodes, soft tissue — and treat them with precision.
In March 2022, the FDA approved Lu-177 PSMA-617 (brand name Pluvicto) for PSMA-positive mCRPC, following results from the phase 3 VISION trial.
What the VISION Trial Found
The VISION trial enrolled men with PSMA-positive mCRPC who had already received at least one ARPI (such as enzalutamide or abiraterone) and at least one course of docetaxel chemotherapy.
Participants received either Lu-177 PSMA-617 plus standard care, or standard care alone. According to the National Cancer Institute, adding Lu-177 PSMA-617 cut the risk of death by 38% and disease progression by 60% compared to standard care alone. Median overall survival improved from 11.3 months to 15.3 months.
Quality of life also improved. A published analysis of VISION data found that Lu-177 PSMA-617 delayed the time to worsening of pain and health-related quality of life compared to the control group. For men managing bone pain and other daily symptoms, this matters.
What the PSMAfore Trial Adds
The VISION trial enrolled men who had already received chemotherapy. But what about men who have not yet had taxane-based chemo? The PSMAfore trial addressed this question.
PSMAfore compared Lu-177 PSMA-617 against switching to a different ARPI in men who had received one ARPI but no prior taxane chemotherapy. Results showed that Lu-177 PSMA-617 may offer better disease control than simply switching hormone drugs at this stage — with a median radiographic progression-free survival of 12.0 months versus 5.6 months for the ARPI-switch group.
A review of Lu-177 PSMA trial data also found that in direct comparisons with cabazitaxel chemotherapy, Lu-177 PSMA therapy had about double the PSA response rate and fewer severe side effects. These findings do not mean Lu-177 PSMA is right for every patient — eligibility still depends on PSMA expression and other factors — but they show a stronger profile compared to the standard chemotherapy option at this stage.
The PSMAfore data is changing how oncologists think about treatment order. If your team has suggested chemotherapy first, it may be worth asking whether Lu-177 PSMA is appropriate at your current stage. Our article on whether to get a second opinion on treatment order before chemotherapy explores this question in more depth.
Who May Be Eligible
Eligibility for Lu-177 PSMA therapy is based on several factors, reviewed by a specialist before treatment begins. Typical requirements include:
- A PSMA PET scan confirming PSMA-positive disease (using Ga-68 PSMA-11 or a similar approved agent)
- Documented disease progression while on hormone therapy, confirming mCRPC status
- Prior treatment with at least one second-generation ARPI
- Prior taxane-based chemotherapy (per the current standard approved indication)
- Adequate kidney, liver, and bone marrow function
- No rapidly growing lesions that are PSMA-negative, which would not respond to this therapy
Eligibility criteria are evolving as new trial data emerges. Some centers offer access at earlier stages through clinical trials or expanded access programs. If you have been told you do not qualify, a second opinion from a radioligand therapy specialist may show options not previously considered. Our guide to understanding Lu-177 PSMA eligibility and getting a second opinion covers this in detail.
Side Effects: What to Expect and How They Compare
Lu-177 PSMA therapy has manageable side effects. The most commonly reported effects include:
- Fatigue, often mild to moderate and temporary
- Dry mouth (xerostomia) — this may persist in some patients because PSMA is also expressed in the salivary glands
- Nausea, usually mild
- Temporary drops in blood cell counts, including anemia, low platelets, and low white blood cells
- Mild kidney stress, monitored closely through blood tests before each cycle
Compared to taxane chemotherapy, Lu-177 PSMA causes less hair loss and nerve damage and has fewer serious infections. Compared to ARPI drugs, it avoids some cardiovascular and cognitive risks.
Serious side effects are possible. Your care team will manage them throughout treatment. Blood tests before each cycle let your team catch and address concerns early.
What International Patients Should Know
Lu-177 PSMA therapy is available at specialist nuclear medicine centers in India, including Mumbai, Hyderabad, Chennai, and Bangalore. Treatment costs in India are significantly lower than in the United States, United Kingdom, Australia, or Western Europe — while using the same Lu-177 PSMA-617 compound studied worldwide.
Treatment is typically delivered over up to 6 cycles, each spaced about 6 weeks apart. International patients often plan two or three visits to India over the course of a full treatment program. Most specialist centers have international patient coordinators who help with scheduling, accommodation, visa support, and coordination with your home oncologist.
Our detailed guide on planning your Lu-177 PSMA treatment cycle in India covers preparation steps, what to expect on arrival, and how to maintain continuity of care with your team back home.
When to Talk to Your Doctor
Speak with your oncologist or a nuclear medicine specialist if any of the following apply:
- Your PSA has been rising despite hormone therapy
- New lesions have appeared on imaging scans
- You have not yet had a PSMA PET scan and want to understand your PSMA expression status
- You are weighing next-line options and want to understand where Lu-177 PSMA fits into the sequence
- You have been told Lu-177 PSMA is not suitable for you and want a second opinion
The right time to explore your options is before the cancer has progressed further. A specialist in radioligand therapy can review your scan results and treatment history to tell you what options might work for your case.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
What does castration-resistant prostate cancer actually mean?
Castration-resistant prostate cancer means the cancer keeps growing even when testosterone levels have been suppressed very low — below 50 ng/dL — through hormone therapy. The word castrate refers to this low-testosterone state. Cancer cells have found ways to keep growing without their usual fuel. This does not mean there are no more treatment options. Several treatments, including Lu-177 PSMA therapy, have shown meaningful results at this stage of disease.
Do I need to complete chemotherapy before I can access Lu-177 PSMA therapy?
Under the standard FDA-approved label for Pluvicto (Lu-177 PSMA-617), patients are typically required to have received at least one second-generation hormone therapy and at least one course of taxane-based chemotherapy. However, this is changing. The PSMAfore trial showed encouraging results in men who had not yet received chemotherapy. Some centers offer access through clinical trials or expanded access programs. If your team is recommending chemotherapy first, it may be worth asking a radioligand therapy specialist whether Lu-177 PSMA could be considered at your current stage.
How do I find out if I am PSMA-positive?
A PSMA PET scan — typically using Ga-68 PSMA-11 or F-18 DCFPyL — is the test used to confirm PSMA-positive disease. A small amount of a PSMA-targeting radiotracer is injected into your bloodstream, and cancer cells that express PSMA show up clearly on the scan. The scan reveals where PSMA-positive tumors are in your body and how strongly they express the target protein. Not all prostate cancers are PSMA-positive, which is why this scan is a required step before starting Lu-177 PSMA therapy. Your oncologist can order this scan or refer you to a nuclear medicine specialist.
Can I receive Lu-177 PSMA therapy in India if I live in the UK, US, or Australia?
Yes. Several specialist nuclear medicine centers in India treat international patients from the UK, US, Australia, Canada, the UAE, and other countries. The therapy uses the same Lu-177 PSMA-617 compound studied in global clinical trials. International patient coordinators at these centers help with scheduling, accommodation, and communication with your home oncologist. Most patients plan 2 to 3 visits over the course of a standard 6-cycle program. Costs in India are typically a fraction of what the same treatment would cost in Western countries.
What is the typical treatment schedule for Lu-177 PSMA therapy?
Most patients receive up to 6 cycles of Lu-177 PSMA therapy, with each cycle spaced approximately 6 weeks apart. Each infusion typically takes 30 minutes to one hour, followed by a few hours of radiation safety monitoring at the facility. Blood tests — and sometimes imaging scans — are done before each cycle to check kidney function, blood counts, and treatment response. Between cycles, most patients are able to return to normal daily activities.
Will Lu-177 PSMA therapy cure my prostate cancer?
Current clinical evidence does not describe Lu-177 PSMA therapy as a cure for mCRPC. What the research — particularly the VISION trial — shows is that it may meaningfully slow disease progression, extend overall survival, and improve quality of life compared to standard care alone in men with PSMA-positive disease. The goal of treatment at this stage is typically to control the cancer, manage symptoms, and support quality of life for as long as possible. Your oncologist can help you set realistic goals based on your specific situation.